Annovis Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANVS New York 2830 www.annovisbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annovis Bio, Inc.

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - Apr 10th, 2026 6:30 am
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - Apr 9th, 2026 6:30 am
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - Apr 2nd, 2026 5:30 am
Annovis Publishes Historical Review of Buntanetap in The Scientist - Mar 31st, 2026 6:00 am
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - Mar 19th, 2026 5:30 am
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - Mar 19th, 2026 5:30 am
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Mar 16th, 2026 5:30 am
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - Mar 3rd, 2026 6:00 am
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease - Feb 12th, 2026 6:00 am
Automotive Night Vision System Market to Reach US$ 9,138.4 Million by 2032 Driven by AI-Enabled Predictive Safety and Mainstream Adoption Beyond Luxury Vehicles | Astute Analytica - Feb 10th, 2026 5:54 am
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - Dec 18th, 2025 2:35 pm
Annovis to Host Corporate Update Webinar on January 28, 2026 - Dec 16th, 2025 6:00 am
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Dec 3rd, 2025 6:00 am
Annovis Announces Two Presentations at the CTAD 2025 Conference - Nov 24th, 2025 6:00 am
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study - Nov 18th, 2025 6:00 am
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients - Nov 17th, 2025 6:00 am
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results - Nov 12th, 2025 6:00 am
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program - Nov 6th, 2025 6:00 am
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules - Oct 27th, 2025 6:00 am
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock - Oct 15th, 2025 3:15 pm